M. Bilal Abid, Medical Director, Blood and Marrow Transplantation and Cellular Therapy Program at Texas Tech University Health Sciences Center, shared a post by AJMC – The American Journal of Managed Care on LinkedIn, adding:
“My thoughts on immune paradox associated with engineered T-cell therapies and accompanying immune compromise.
Time is right to optimize antimicrobial prophylaxis, IVIG replacements, myeloid growth factors, further supplemented by novel preexposure and postexposure prophylaxis platforms for severely compromised patients!
Thanks, AJMC – The American Journal of Managed Care for the invitation and disseminating the message!”
Quoting AJMC‘s post:
“How do you weigh the risk of infection against the promise of immune-engaging and engineered T-cell therapies?
In the pilot episode of The Abid Perspective, M. Bilal Abid MD, MS, FACP, MRCP, FRCP, medical director of blood and marrow transplantation and cellular therapy at Texas Tech University Health Sciences Center, tackles this delicate tradeoff head-on-delivering the kind of concise, clinically grounded perspective that practitioners navigating advanced therapeutics need.
This is the first installment of his new short video series at the intersection of immunology, infectious disease, and oncology.”
Other articles about Immunology on OncoDaily.